Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Vink, FJ, Meijer, CJLM, Clifford, GM, Poljak, M, Oštrbenk, A, Petry, KU, Rothe, B, Bonde, J, Pedersen, H, de Sanjosé, S, Torres, M, Del Pino, M, Quint, WGV, Cuschieri, K, Alcañiz Boada, E, van Trommel, NE, Lissenberg-Witte, BI, Floore, AN, Hesselink, AT, Steenbergen, RDM, Bleeker, MCG & Heideman, DAM 2020, 'FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study' International Journal of Cancer, vol. 147, no. 4, pp. 1215-1221. https://doi.org/10.1002/ijc.32614

APA

Vink, F. J., Meijer, C. J. L. M., Clifford, G. M., Poljak, M., Oštrbenk, A., Petry, K. U., ... Heideman, D. A. M. (2020). FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study. International Journal of Cancer, 147(4), 1215-1221. https://doi.org/10.1002/ijc.32614

CBE

Vink FJ, Meijer CJLM, Clifford GM, Poljak M, Oštrbenk A, Petry KU, Rothe B, Bonde J, Pedersen H, de Sanjosé S, Torres M, Del Pino M, Quint WGV, Cuschieri K, Alcañiz Boada E, van Trommel NE, Lissenberg-Witte BI, Floore AN, Hesselink AT, Steenbergen RDM, Bleeker MCG, Heideman DAM. 2020. FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study. International Journal of Cancer. 147(4):1215-1221. https://doi.org/10.1002/ijc.32614

MLA

Vancouver

Author

Vink, Frederique J ; Meijer, Chris J L M ; Clifford, Gary M ; Poljak, Mario ; Oštrbenk, Anja ; Petry, Karl Ulrich ; Rothe, Beate ; Bonde, Jesper ; Pedersen, Helle ; de Sanjosé, Silvia ; Torres, Montserrat ; Del Pino, Marta ; Quint, Wim G V ; Cuschieri, Kate ; Alcañiz Boada, Elia ; van Trommel, Nienke E ; Lissenberg-Witte, Birgit I ; Floore, Arno N ; Hesselink, Albertus T ; Steenbergen, Renske D M ; Bleeker, Maaike C G ; Heideman, Daniëlle A M. / FAM19A4/miR124-2 methylation in invasive cervical cancer : A retrospective cross-sectional worldwide study. In: International Journal of Cancer. 2020 ; Vol. 147, No. 4. pp. 1215-1221.

Bibtex

@article{02756ad2087843c4b657235438e4604e,
title = "FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study",
abstract = "Widespread adoption of primary human papillomavirus (HPV)-based screening has encouraged the search for a triage test which retains high sensitivity for the detection of cervical cancer and precancer, but increases specificity to avoid overtreatment. Methylation analysis of FAM19A4 and miR124-2 genes has shown promise for the triage of high-risk (hr) HPV-positive women. In our study, we assessed the consistency of FAM19A4/miR124-2 methylation analysis in the detection of cervical cancer in a series of 519 invasive cervical carcinomas (n = 314 cervical scrapes, n = 205 tissue specimens) from over 25 countries, using a quantitative methylation-specific PCR (qMSP)-based assay (QIAsure Methylation Test{\circledR}). Positivity rates stratified per histotype, FIGO stage, hrHPV status, hrHPV genotype, sample type and geographical region were calculated. In total, 510 of the 519 cervical carcinomas (98.3{\%}; 95{\%} CI: 96.7–99.2) tested FAM19A4/miR124-2 methylation-positive. Test positivity was consistent across the different subgroups based on cervical cancer histotype, FIGO stage, hrHPV status, hrHPV genotype, sample type and geographical region. In conclusion, FAM19A4/miR124-2 methylation analysis detects nearly all cervical carcinomas, including rare histotypes and hrHPV-negative carcinomas. These results indicate that a negative FAM19A4/miR124-2 methylation assay result is likely to rule out the presence of cervical cancer.",
keywords = "biomarker, cervical carcinoma, cervical screening, DNA hypermethylation, human genome methylation, human papillomavirus",
author = "Vink, {Frederique J} and Meijer, {Chris J L M} and Clifford, {Gary M} and Mario Poljak and Anja Oštrbenk and Petry, {Karl Ulrich} and Beate Rothe and Jesper Bonde and Helle Pedersen and {de Sanjos{\'e}}, Silvia and Montserrat Torres and {Del Pino}, Marta and Quint, {Wim G V} and Kate Cuschieri and {Alca{\~n}iz Boada}, Elia and {van Trommel}, {Nienke E} and Lissenberg-Witte, {Birgit I} and Floore, {Arno N} and Hesselink, {Albertus T} and Steenbergen, {Renske D M} and Bleeker, {Maaike C G} and Heideman, {Dani{\"e}lle A M}",
note = "{\circledC} 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.",
year = "2020",
month = "8",
day = "15",
doi = "10.1002/ijc.32614",
language = "English",
volume = "147",
pages = "1215--1221",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "JohnWiley & Sons, Inc",
number = "4",

}

RIS

TY - JOUR

T1 - FAM19A4/miR124-2 methylation in invasive cervical cancer

T2 - A retrospective cross-sectional worldwide study

AU - Vink, Frederique J

AU - Meijer, Chris J L M

AU - Clifford, Gary M

AU - Poljak, Mario

AU - Oštrbenk, Anja

AU - Petry, Karl Ulrich

AU - Rothe, Beate

AU - Bonde, Jesper

AU - Pedersen, Helle

AU - de Sanjosé, Silvia

AU - Torres, Montserrat

AU - Del Pino, Marta

AU - Quint, Wim G V

AU - Cuschieri, Kate

AU - Alcañiz Boada, Elia

AU - van Trommel, Nienke E

AU - Lissenberg-Witte, Birgit I

AU - Floore, Arno N

AU - Hesselink, Albertus T

AU - Steenbergen, Renske D M

AU - Bleeker, Maaike C G

AU - Heideman, Daniëlle A M

N1 - © 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

PY - 2020/8/15

Y1 - 2020/8/15

N2 - Widespread adoption of primary human papillomavirus (HPV)-based screening has encouraged the search for a triage test which retains high sensitivity for the detection of cervical cancer and precancer, but increases specificity to avoid overtreatment. Methylation analysis of FAM19A4 and miR124-2 genes has shown promise for the triage of high-risk (hr) HPV-positive women. In our study, we assessed the consistency of FAM19A4/miR124-2 methylation analysis in the detection of cervical cancer in a series of 519 invasive cervical carcinomas (n = 314 cervical scrapes, n = 205 tissue specimens) from over 25 countries, using a quantitative methylation-specific PCR (qMSP)-based assay (QIAsure Methylation Test®). Positivity rates stratified per histotype, FIGO stage, hrHPV status, hrHPV genotype, sample type and geographical region were calculated. In total, 510 of the 519 cervical carcinomas (98.3%; 95% CI: 96.7–99.2) tested FAM19A4/miR124-2 methylation-positive. Test positivity was consistent across the different subgroups based on cervical cancer histotype, FIGO stage, hrHPV status, hrHPV genotype, sample type and geographical region. In conclusion, FAM19A4/miR124-2 methylation analysis detects nearly all cervical carcinomas, including rare histotypes and hrHPV-negative carcinomas. These results indicate that a negative FAM19A4/miR124-2 methylation assay result is likely to rule out the presence of cervical cancer.

AB - Widespread adoption of primary human papillomavirus (HPV)-based screening has encouraged the search for a triage test which retains high sensitivity for the detection of cervical cancer and precancer, but increases specificity to avoid overtreatment. Methylation analysis of FAM19A4 and miR124-2 genes has shown promise for the triage of high-risk (hr) HPV-positive women. In our study, we assessed the consistency of FAM19A4/miR124-2 methylation analysis in the detection of cervical cancer in a series of 519 invasive cervical carcinomas (n = 314 cervical scrapes, n = 205 tissue specimens) from over 25 countries, using a quantitative methylation-specific PCR (qMSP)-based assay (QIAsure Methylation Test®). Positivity rates stratified per histotype, FIGO stage, hrHPV status, hrHPV genotype, sample type and geographical region were calculated. In total, 510 of the 519 cervical carcinomas (98.3%; 95% CI: 96.7–99.2) tested FAM19A4/miR124-2 methylation-positive. Test positivity was consistent across the different subgroups based on cervical cancer histotype, FIGO stage, hrHPV status, hrHPV genotype, sample type and geographical region. In conclusion, FAM19A4/miR124-2 methylation analysis detects nearly all cervical carcinomas, including rare histotypes and hrHPV-negative carcinomas. These results indicate that a negative FAM19A4/miR124-2 methylation assay result is likely to rule out the presence of cervical cancer.

KW - biomarker

KW - cervical carcinoma

KW - cervical screening

KW - DNA hypermethylation

KW - human genome methylation

KW - human papillomavirus

UR - http://www.scopus.com/inward/record.url?scp=85073936712&partnerID=8YFLogxK

U2 - 10.1002/ijc.32614

DO - 10.1002/ijc.32614

M3 - Journal article

VL - 147

SP - 1215

EP - 1221

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -

ID: 57728908